JP2011528336A - 疎水性分子のバイオアベイラビリティを改善するために意図される調合物 - Google Patents

疎水性分子のバイオアベイラビリティを改善するために意図される調合物 Download PDF

Info

Publication number
JP2011528336A
JP2011528336A JP2011517965A JP2011517965A JP2011528336A JP 2011528336 A JP2011528336 A JP 2011528336A JP 2011517965 A JP2011517965 A JP 2011517965A JP 2011517965 A JP2011517965 A JP 2011517965A JP 2011528336 A JP2011528336 A JP 2011528336A
Authority
JP
Japan
Prior art keywords
use according
trihydroxystilbene
glycol
ether
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011517965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528336A5 (enExample
Inventor
ペシェール，ローラン
Original Assignee
イブリー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イブリー filed Critical イブリー
Publication of JP2011528336A publication Critical patent/JP2011528336A/ja
Publication of JP2011528336A5 publication Critical patent/JP2011528336A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011517965A 2008-07-18 2009-07-16 疎水性分子のバイオアベイラビリティを改善するために意図される調合物 Pending JP2011528336A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0804098 2008-07-18
FR0804098A FR2933871B1 (fr) 2008-07-18 2008-07-18 Formulation destinee a ameliorer la biodisponibilite d'une molecule hydrophobe
PCT/FR2009/000868 WO2010007252A2 (fr) 2008-07-18 2009-07-16 Formulation destinée à améliorer la biodisponibilité d'une molécule hydrophobe

Publications (2)

Publication Number Publication Date
JP2011528336A true JP2011528336A (ja) 2011-11-17
JP2011528336A5 JP2011528336A5 (enExample) 2012-08-23

Family

ID=40377450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517965A Pending JP2011528336A (ja) 2008-07-18 2009-07-16 疎水性分子のバイオアベイラビリティを改善するために意図される調合物

Country Status (7)

Country Link
US (1) US20110184072A1 (enExample)
EP (1) EP2315583B1 (enExample)
JP (1) JP2011528336A (enExample)
CA (1) CA2730534C (enExample)
ES (1) ES2686596T3 (enExample)
FR (1) FR2933871B1 (enExample)
WO (1) WO2010007252A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518034A (ja) * 2010-01-21 2013-05-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 薬物として使用するための特別な組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
CA3023725C (en) 2009-10-22 2021-09-14 Vizuri Health Sciences Llc Methods of producing hydrated flavonoids and use thereof in the preparation of topical compositions
EP2629763B1 (en) * 2010-10-22 2017-12-06 Vizuri Health Sciences LLC Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
CN115236250A (zh) * 2022-06-27 2022-10-25 武汉轻工大学 一种乳液对白藜芦醇的生物利用度改善效果的检测方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030336A2 (en) * 1999-10-29 2001-05-03 Pharmascience Pharmaceutical formulations comprising resveratrol and use thereof
JP2002326905A (ja) * 2001-02-21 2002-11-15 L'oreal Sa 少なくとも１種のヒドロキシスチルベンとヒドロキシスチルベンの安定化のために少なくとも１種のポリオールを含有する局所適用用組成物
JP2003231684A (ja) * 2002-02-06 2003-08-19 Ichimaru Pharcos Co Ltd コレステロール代謝改善剤
JP2007314472A (ja) * 2006-05-26 2007-12-06 Oriza Yuka Kk 体臭抑制剤
WO2008023266A2 (en) * 2006-05-05 2008-02-28 Gmbh, Omnica Kiwi extract
JP2008088123A (ja) * 2006-10-03 2008-04-17 Oriza Yuka Kk 美肌用組成物
JP2008239576A (ja) * 2007-03-28 2008-10-09 Koei Kogyo Kk ブドウの芽及び蔓から抽出したレスベラトロール類を含有する組成物
JP2008290982A (ja) * 2007-05-25 2008-12-04 Oriza Yuka Kk 水溶性スチルベン粉末製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329503A1 (de) * 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
IT1286778B1 (it) * 1996-11-20 1998-07-17 Alfa Wassermann Spa Capsule contenenti diclofenac o suoi sali in soluzione
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
IL138616A0 (en) * 2000-09-21 2001-10-31 J P M E D Ltd Oil in glycerin emulsion
US6890547B1 (en) * 1999-07-16 2005-05-10 Amato Pharmaceutical Products, Ltd. Glycyrrhizin preparations for transmucosal absorption
PE20010540A1 (es) * 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
WO2004071490A1 (en) * 2003-02-12 2004-08-26 R & P Korea Co., Ltd. Solvent system of hardly soluble drug with improved elution rate
ES2344920T3 (es) * 2006-03-28 2010-09-09 Epitech Group S.R.L. Composicion farmaceutica para el tratamiento de patologias provocadas por la respuesta general del sistema inmutario.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030336A2 (en) * 1999-10-29 2001-05-03 Pharmascience Pharmaceutical formulations comprising resveratrol and use thereof
JP2002326905A (ja) * 2001-02-21 2002-11-15 L'oreal Sa 少なくとも１種のヒドロキシスチルベンとヒドロキシスチルベンの安定化のために少なくとも１種のポリオールを含有する局所適用用組成物
JP2003231684A (ja) * 2002-02-06 2003-08-19 Ichimaru Pharcos Co Ltd コレステロール代謝改善剤
WO2008023266A2 (en) * 2006-05-05 2008-02-28 Gmbh, Omnica Kiwi extract
JP2007314472A (ja) * 2006-05-26 2007-12-06 Oriza Yuka Kk 体臭抑制剤
JP2008088123A (ja) * 2006-10-03 2008-04-17 Oriza Yuka Kk 美肌用組成物
JP2008239576A (ja) * 2007-03-28 2008-10-09 Koei Kogyo Kk ブドウの芽及び蔓から抽出したレスベラトロール類を含有する組成物
JP2008290982A (ja) * 2007-05-25 2008-12-04 Oriza Yuka Kk 水溶性スチルベン粉末製剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518034A (ja) * 2010-01-21 2013-05-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 薬物として使用するための特別な組成物

Also Published As

Publication number Publication date
EP2315583A2 (fr) 2011-05-04
US20110184072A1 (en) 2011-07-28
WO2010007252A2 (fr) 2010-01-21
CA2730534A1 (fr) 2010-01-21
EP2315583B1 (fr) 2018-05-09
ES2686596T3 (es) 2018-10-18
WO2010007252A3 (fr) 2010-12-16
FR2933871A1 (fr) 2010-01-22
CA2730534C (fr) 2017-10-24
FR2933871B1 (fr) 2012-12-14

Similar Documents

Publication Publication Date Title
RU2462250C2 (ru) Новая композиция, основанная на оксиме холест-4-ен-3-она
EP3431075B1 (en) Edaravone dosage form
EP2459221B1 (fr) Formulation pharmaceutique
AU2019205118A1 (en) Modified release composition comprising a cannabinoid
AU2017287868A1 (en) Cannabinoid formulations
DK2523666T3 (en) A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
CN1615146A (zh) 生姜提取物制剂
JP2011528336A (ja) 疎水性分子のバイオアベイラビリティを改善するために意図される調合物
JP2022518356A (ja) レラコリラント含有医薬製剤、ヘテロアリールケトン縮合アザデカリン化合物
JP5528799B2 (ja) 改善されたバイオアベイラビリティを有するオリーブの果実又は葉の抽出物のリン脂質複合体
JP5325779B2 (ja) 医薬組成物
WO2008022557A1 (fr) Composition liquide de sirolimus
JP2006524190A (ja) 薬剤のメントール溶液
US20150065442A1 (en) Reducible self-assembled micelle drug delivery systems
KR102228135B1 (ko) 레스베라트롤을 포함하는 고형 제제 형태의 약학 조성물 및 레스베라트롤의 가용화 방법
KR20190040305A (ko) 체중 감소를 위한 피하 주사제 및 그의 용도
EP1713442A1 (en) Semisolid matrix pharmaceutical formulations
US11382871B2 (en) Pharmaceutical composition containing curcumin
US11446259B2 (en) Curcuminoid compositions and preparation methods
JP2013518034A (ja) 薬物として使用するための特別な組成物
CN113521308B (zh) 一种塞来昔布与没食子酸改性磺丁基倍他环糊精钠的包合物及其制备方法
Susanto et al. Increased Anti-Proliferation Performance of NanoChitosan-Moringa Seeds Extract and Co-Treatment with Doxorubicin in Liver Cancer Cells
WO2025084940A1 (en) 2-methyl-3-phytyl-1,4-naphthoquinone for use in the treatment or prevention of diseases with dysfunction of vascular endothelium
WO2025248298A1 (en) Novel curcumin nano-formulation and process for preparation thereof
EP3946407A1 (en) Formulation to enhance the bioavailibity and stability of curcuminoids and/or its derivatives thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140430

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140610